Exploring CAR-T Therapy in Early Lines of Relapsed/Refractory Multiple Myeloma

Opinion
Video

Panelists discuss the data surrounding the use of CAR-T therapy in earlier lines of treatment for relapsed/refractory multiple myeloma (R/R MM), including findings from the cilta-cel (Popat R, et al. ASH 2024 No. 1032; Mateos MV, et al. IMS 2024 No. OA-65), and Idel-cel (Ailawadhi S, et al. Blood 2024) studies, and share their thoughts on the implications of these results.

Seg01_Exploring
Video Player is loading.
Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      Video content above is prompted by the following:

      • Let’s talk about the data surrounding the use of CAR-T therapy in earlier lines of treatment for R/RMM:
      • Cilta-cel
      • Ide
      • What are your thoughts around about these data?
      Related Content